Primary objective
Comparison of the prevalence of molecular alterations between the post-treatment versus pre-treatment tumor samples of all patients.
Secondary objectives
* Comparison of the prevalence of molecular alterations between the post-treatment versus pre-treatment tumor samples of patients with paired samples (post- and pre-treatment)
* Identification of molecular alterations in the pre-treatment samples associated with the clinical benefit (RECIST responses, progression-free survival PFS)
* Identification of expression signature in the pre-treatment samples associated with the clinical benefit (RECIST1.1 responses, progression-free survival PFS)
* Identification of molecular alterations therapeutically “actionable” (therapeutic target of or marker predictive for response to currently available or under development drugs) in the post- and the pre-treatment samples
*Percentage of patients with molecular alterations therapeutically “actionable” in the post- and the pre-treatment samples
Institut Paoli Calmettes
232 Boulevard Sainte Marguerite
13273 Marseille Cedex 09
The main inclusion criteria include female patients previously treated in our institution, with pathologically-proven HR+/HER2- mBC, treated with hormone therapy combined with CDK4/6 inhibitors, with a metastatic/tumor sample (FFPE and/or frozen) available and collected before and/or after this treatment, with clinico-pathological annotations including the dates of treatments, objective responses, and progression-free survival, and with signed informed consent for enrolment and molecular analyses. All patients v and not lost to follow-up will be sent an individual information note before launching the project to advertise them of the project.
Traitement de données mené dans l'intérêt public dans le domaine de la santé publique (article 6.1e et 9.2.j du Règlement (UE) n°2016/679)
Institut Paoli Calmettes
Les données seront conservées pendant la durée légale en vigueur ou tant qu'elles présenteront un intérêt scientifique